Dr. Sneha Swaroop,Lecturer
Information about Dr. Sneha Swaroop at the University of Bradford.
- School of Pharmacy & Medical Sciences
(Faculty of Life Sciences) - Email:
- s.swaroop@bradford.ac.uk
Biography
Dr Sneha Swaroop is a Lecturerin Cell and Molecular Biology at the School of Pharmacy and Medical Sciences.Her research focuses on stem cells in cancer, with the goal of identifying novelways to target them and develop effective therapies for cancer patients. Afterearning her Master’s degree in Biotechnology, Dr Swaroop pursued a Ph.D. in thefield of Oncology from the renowned Cancer Institute (WIA), India, where sheextensively researched the role of the hedgehog pathway in maintaining cancerstem cells in serous adenocarcinoma of the ovary. As a testament to her excellentresearch capabilities, Dr Swaroop was awarded the prestigious SchlumbergerFaculty for the Future (FFTF) Fellowship, allowing her to undertake post- doctoralresearch in drug discovery at the Institute of Cancer Therapeutics (ICT),University of Bradford. In this role, she evaluated novel cancer stemcell-targeted chemical probes and drug candidates in breast and prostate cancer,which has the potential to transform cancer treatment. Aside from her research,Dr Swaroop is also a dedicated STEM ambassador and educator, mentoring andtraining the next generation of scientists. She is also committed to engagingwith wider community, participating in public engagement activities increasingawareness and understanding of cancer research.Research
Dr Sneha Swaroop’s research interestsare centered around understanding the intricate biology of cancer stem cellsand identifying novel ways to target them. Her research includes several noteworthystudies such as:1) Characterising ovarian cancer stem cells (CSCs) usingspheroid culture and evaluating the significance of embryonic signalingpathways.
2) Identifyingnovel biomarkers for ovarian cancer stem cells using in silico approaches, establishingin vitro and in vivo models to study CSCs and evaluating novel therapeutictargets for improved treatment.
3) Evaluationof the effect of a dual PI3K δ/γ inhibitors on cancer stem cell proliferationin serous ovarian carcinoma.
4) Investigating stem cell gene expression inspheroids and deciphering splice variants of stem cell specific genes interatoma and human embryonic stem cells followed by their analysis in two and threedimensional culture.
5) Establishing the role of CSCs in tumourangiogenesis and lymph angiogenesis in ovarian cancer.
Movingforward, Dr Swaroop aims to continue exploring the biology of cancer stem cellsin relation to the tumour microenvironment with the ultimate aim of developingmore effective treatments for cancer patients.
Currently Dr Swaroop is seeking motivated and passionate PhD students and Post Docs to explore the intricate self regulatory mechanisms of CSCs in ovarian cancer. Fellowship applications such as Schlumberger, Newton and Commonwealth from ideal candidates will be supported for conducting research in the filed of CSCs at the Institute of Cancer Therapeutics, Bradford. Please contact s.swaroop@bradford.ac.uk for more details.
Publications
There are 15 publications involving or that are attributed to Dr. Sneha Swaroop.
Peer Reviewed Journal
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic antibodies against cancer stem cells: a promising approach. | 2017 | Cancer Immunology, Immunotherapy | 66 | Sneha S;Nagare RP;Priya SK;Sidhanth C;Pors K;Ganesan TS; | 1432-0851 | 10.1007/s00262-017-2049-0 | |||||
| Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. | 2021 | Biomedicines | 9 | Sneha S;Baker SC;Green A;Storr S;Aiyappa R;Martin S;Pors K; | 2227-9059 | 10.3390/biomedicines9030290 | |||||
| Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
| Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer | 2022 | Journal of Medicinal Chemistry | 65 | Ali I M Ibrahim, Elisabet Batlle, Smarakan Sneha, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Till Rüngeler, Vibhu Jha, Tiziano Tuccinardi, Maria Sadiq, Fiona Frame, Norman J Maitland, Jaume Farrés, Klaus Pors | 10.1021/acs.jmedchem.1c01367 | ||||||
| Analysis of hematopoietic stem cells using a composite approach. | 2019 | International Journal of Biochemistry and Cell Biology | 109 | Nagare RP;Sneha S;Ramesh S;Ganesan TS; | 1878-5875 | 10.1016/j.biocel.2019.02.003 | |||||
| Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. | 2020 | Cancer Biomarkers : Section A Of Disease Markers | 28 | Nagare RP;Sneha S;Sidhanth C;Roopa S;Murhekar K;Shirley S;Swaminathan R;Sridevi V;Ganesan TS; | 1875-8592 | 10.3233/CBM-201463 | |||||
| ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. | 2020 | Experimental Cell Research | 392 | Nagare RP;Sneha S;Krishnapriya S;Ramachandran B;Murhekar K;Vasudevan S;Shabna A;Ganesan TS; | 1090-2422 | 10.1016/j.yexcr.2020.112009 | |||||
| LASP-1 interacts with ErbB2 in ovarian cancer cells. | 2022 | Biochemical Journal | 479 | Sidhanth C;Bindhya S;Shabna A;Krishnapriya S;Manasa P;Nagare RP;Joshua T;Sneha S;Murhekar K;Ganesan TS; | 1470-8728 | 10.1042/BCJ20210173 | |||||
| Cancer Stem Cells - Are Surface Markers Alone Sufficient? | 2017 | Current Stem Cell Research and Therapy | 12 | Nagare RP;Sneha S;Priya SK;Ganesan TS; | 2212-3946 | 10.2174/1574888x11666160607211436 | |||||
| The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. | 2020 | Cellular Oncology (Dordrecht) | 43 | Sneha S;Nagare RP;Sidhanth C;Krishnapriya S;Garg M;Ramachandran B;Murhekar K;Sundersingh S;Ganesan TS; | 2211-3436 | 10.1007/s13402-020-00504-w | |||||
| Analysis of Human Stem Cell Transcription Factors. | 2019 | Cellular Reprogramming | 21 | Sneha S;Nagare RP;Manasa P;Vasudevan S;Shabna A;Ganesan TS; | 2152-4998 | 10.1089/cell.2019.0005 | |||||
| Tumour angiogenesis-Origin of blood vessels. | 2016 | International Journal of Cancer | 139 | Krishna Priya S;Nagare RP;Sneha VS;Sidhanth C;Bindhya S;Manasa P;Ganesan TS; | 1097-0215 | 10.1002/ijc.30067 | |||||
| A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. | 2018 | Biochemistry and cell biology = Biochimie et biologie cellulaire | 96 | Sidhanth C;Manasa P;Krishnapriya S;Sneha S;Bindhya S;Nagare RP;Garg M;Ganesan TS; | 1208-6002 | 10.1139/bcb-2017-0020 | |||||
| Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. | 2017 | Scientific Reports | 7 | Garg M;Kanojia D;Mayakonda A;Ganesan TS;Sadhanandhan B;Suresh S;S S;Nagare RP;Said JW;Doan NB;Ding LW;Baloglu E;Shacham S;Kauffman M;Koeffler HP; | 2045-2322 | 10.1038/s41598-017-10325-x | |||||
| Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. | 2019 | Angiogenesis | 22 | Krishnapriya S;Sidhanth C;Manasa P;Sneha S;Bindhya S;Nagare RP;Ramachandran B;Vishwanathan P;Murhekar K;Shirley S;Ganesan TS; | 1573-7209 | 10.1007/s10456-019-09669-x |